GLAXOSMITHKLINE PLC Form 6-K August 10, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 10 August 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA') a) Name

Sir Andrew Witty

b)Position/status CEO

c) Initial notification/

Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction

² platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

c) Price(s) and volume(s) £16.79758 (partnership shares)

£16.79758 (matching shares)

Aggregated information

b) Nature of the transaction

d) 16 Ordinary shares

Aggregated volume Price £16.7975

e) Date of the transaction 2016-08-09

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b)Position/status

President, Global

Manufacturing & Supply

Initial notification/
c) amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction

². platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

£16.79758 (partnership shares) c) Price(s) and volume(s)

£16.79758 (matching shares)

Aggregated information

b) Nature of the transaction

d)

16 Ordinary shares

£16.7975

Aggregated volume Price

e) Date of the transaction

2016-08-09

Place of the transaction

London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b)Position/status CFO

c) Initial notification/

amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b)LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

£16.79758 (partnership shares)

£16.79758 (matching shares)

d) Aggregated information

c) Price(s) and volume(s)

b) Nature of the transaction

Aggregated volume Price 16 Ordinary shares

£16.7975

e) Date of the transaction 2016-08-09

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

SVP, Global Ethics & b)Position/status

Compliance

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name

5493000HZTVUYLO1D793 b)LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

£16.79758 (partnership shares) c) Price(s) and volume(s)

£16.79758 (matching shares)

Aggregated information

d)

b) Nature of the transaction

16 Ordinary shares

£16.7975 Aggregated volume Price

e) Date of the transaction 2016-08-09

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain

President, Global b) Position/status Pharmaceuticals

c) Initial notification/ Initial notification amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's b) Nature of the transaction ShareReward Plan

Price(s) Volume(s)

£16.79757 (partnership shares) c) Price(s) and volume(s)

£16.79757 (matching shares)

Aggregated information

14 Ordinary shares d)

£16.7975

Aggregated volume Price

e) Date of the transaction 2016-08-09

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr D S Redfern a) Name

b)Position/status Chief Strategy Officer

c) Initial notification/ Initial notification amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b)LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence

each

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

£16.79758 (partnership shares) c) Price(s) and volume(s)

£16.79758 (matching shares)

Aggregated information

d)

b) Nature of the transaction

16 Ordinary shares

Aggregated volume Price

£16.7975

e) Date of the transaction 2016-08-09

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas b)Position/status SVP, HR

Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

£16.79758 (partnership shares) c) Price(s) and volume(s)

£16.79758 (matching shares)

Aggregated information

b) Nature of the transaction

16 Ordinary shares

Aggregated volume Price

d)

£16.7975

2016-08-09 e) Date of the transaction

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr P C Thomson a) Name

SVP, Communications & b) Position/status Government Affairs

Initial notification/

Initial notification amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b)LEI Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

c) Price(s) and volume(s) £16.79758 (partnership shares)

£16.79758 (matching shares)

Aggregated information

b) Nature of the transaction

16 Ordinary shares d)

£16.7975 Aggregated volume Price

e) Date of the transaction 2016-08-09

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Dr P J T Vallance a) Name

President, Pharmaceuticals b)Position/status

R&D

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

Price(s) Volume(s)

£16.79757 (partnership shares) c) Price(s) and volume(s)

£16.79757 (matching shares)

Aggregated information

b) Nature of the transaction

14 Ordinary shares d)

£16.7975 Aggregated volume Price

e) Date of the transaction 2016-08-09

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

CEO, GSK Consumer b) Position/status

Healthcare

c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name

5493000HZTVUYLO1D793 b)LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction Acquisition of ordinary shares

under the Company's

ShareReward Plan

Price(s) Volume(s)

c) Price(s) and volume(s) £16.79758 (partnership shares)

£16.79758 (matching shares)

Aggregated information

d)

16 Ordinary shares

Aggregated volume Price

£16.7975

e) Date of the transaction

London Stock Exchange

Place of the transaction

(XLON)

2016-08-09

a) Name Mrs V A Whyte b)Position/status Company Secretary c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's

b) Nature of the transaction ShareReward Plan

Price(s) Volume(s)

£16.79758 (partnership shares) c) Price(s) and volume(s)

£16.79758 (matching shares)

Aggregated information

d)

16 Ordinary shares

Aggregated volume Price

£16.7975

2016-08-09 e) Date of the transaction

f) Place of the transaction London Stock Exchange

(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: August 10, 2016

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc